Who Paid My Doc
Stephen Thomas
Infectious Disease Syracuse, NY Medical Doctor
NPI 1154482339 CMS profile 823056
725 Irving Avenue, Suite 314, Syracuse, NY 13210
General payments
$293,859
Research payments
$12,530
Ownership & investment interest
$0
Research they led as principal investigator
$5,923,112
Through program year 2025, Stephen Thomas of Syracuse, NY is reported in the CMS Open Payments database as having received $293,859 across 152 general payments and $12,530 in research payments paid to them. Separately, studies naming them as principal investigator received $5,923,112 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $67,936 | 31 | |
| 2024 | General | $56,280 | 28 | |
| 2023 | General | $86,944 | 49 | |
| 2022 | General | $26,310 | 16 | |
| 2022 | Research | $1,820 | 1 | |
| 2021 | General | $26,069 | 9 | |
| 2021 | Research | $10,710 | 5 | |
| 2019 | General | $30,320 | 19 |
Beside peers
- Stephen Thomas
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Stephen Thomas were reported at $67,936. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Stephen Thomas | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $30,320 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $26,069 | $148 | $38–$905 | $132 |
| 2022 | $26,310 | $166 | $50–$834 | $149 |
| 2023 | $86,944 | $171 | $57–$787 | $160 |
| 2024 | $56,280 | $176 | $52–$752 | $164 |
| 2025 | $67,936 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
158 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in New York
Harish Moorjani
Infectious Disease · Briarcliff Manor, NY
Sorana Segal- Maurer
Infectious Disease · Flushing, NY
Sian Jones
Infectious Disease · New York, NY
Antonio Urbina
Infectious Disease · New York, NY
David Bekhor
Infectious Disease · New York, NY
Andre Brutus
Infectious Disease · Brooklyn, NY
Related records
Infectious Disease in New York
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.